Analyst Mark Massaro of BTIG reiterated a Buy rating on Guardant Health (GH – Research Report), retaining the price target of $50.00.

With more than 10 miles of Bay shoreline, a Redwood City Council study session focused on its vulnerability to sea-level rise ...

On Tuesday, Canaccord Genuity (TSX:CF) maintained its Buy rating on Exact Sciences (NASDAQ:EXAS) Corporation (NASDAQ:EXAS) and increased the stock's price target to $95 from the previous $75. The firm ...

--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the company will present modeling data evaluating the simulated ...

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the company will present modeling data evaluating the simulated benefit and burden ...

A vacant house in the 400 block of Winnipeg’s Redwood Avenue was set ablaze Sunday ... see someone entering a vacant building, or the city if a vacant structure’s boards become loose or ...

October 27, 2024--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the company will present modeling data ...

Wells Fargo has recently initiated Exact Sciences Corp (EXAS) stock to Overweight rating, as announced on August 28, 2024, according to Finviz. Earlier, on June 27, 2024, Scotiabank had initiated the ...

Exact Sciences EXAS is slated to report its third-quarter 2024 earnings on Nov. 5. Exact Sciences is a leading cancer diagnostics company, which focuses on the development of new and innovative ...